Comparison of ultrastructural changes in thyrotrophs of the rat pituitary between intermittent and continuous treatments with sulfadimethoxine.
To clarify relationships between serum thyroid-stimulating hormone (TSH) levels and ultrastructural changes in thyrotrophs caused by intermittent or continuous treatments with antithyroid compound, male Fischer-344 rats initiated with N-bis(2-hydroxypropyl)nitrosamine (DHPN) were given water containing 0.1% sulfadimethoxine (SM) for 8 wk and then sacrificed (Group 1). Additional groups were examined 2 wk after withdrawal (Group 2), after 4 wk retreatment following a 2-wk withdrawal period (Group 3), and after 14 wk continuous exposure (Group 4). Control rats (Group 5) remained untreated for 8 wk after the DHPN initiation. Microscopic examination revealed hypertrophy of thyrotrophs and depletion of TSH-positive material in Groups 1, 3, and 4 but a return to normal in Group 2. Electron microscopic examination of thyrotrophs in the anterior pituitary in Groups 1, 3, and 4 revealed dilated rough endoplasmic reticulum (ER) cisternae with intracisternal dense granules as well as diminished numbers of intracytoplasmic secretory granules, these changes being most marked in Group 1 and least pronounced in Group 4. The number of intracytoplasmic secretory granules in Group 3 was much lower than in Group 4, as demonstrated by morphometric analysis. In Group 2, thyrotrophs showed dilated rough ER cisternae without intracisternal dense granules and essentially the same component of intracytoplasmic secretory granules as Group 5. The present study suggest that while prolonged continuous treatment with SM results in gradual acclimation to an increased demand for TSH, intermittent treatment elicits a persistent state of reduced TSH storage in thyrotrophs due to a continued strong feedback through the hypothalamus-pituitary-thyroid axis.
Shimo
T
T
Research Department, Hokuriku Seiyaku Co., Ltd., Fukui, Japan.
Mitsumori
K
K
Takahashi
M
M
Katayama
J
J
Saito
A
A
Yoshida
H
H
Aoki
Y
Y
Onodera
H
H
Takahashi
M
M
D000818:Animals; D013956:Antithyroid Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000633:toxicity; D004334:Drug Administration Schedule; D007279:Injections, Subcutaneous; D008297:Male; D009602:Nitrosamines / Q000633:toxicity; D009929:Organ Size / Q000187:drug effects; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000648:ultrastructure*; D051381:Rats; D011916:Rats, Inbred F344; D013412:Sulfadimethoxine / Q000008:administration & dosage* / Q000494:pharmacology*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D013956:Antithyroid Agents; D002273:Carcinogens; D009602:Nitrosamines; D014284:Triiodothyronine; D013412:Sulfadimethoxine; C012457:diisopropanolnitrosamine; D013972:Thyrotropin; D013974:Thyroxine